About NanoPass Technologies Ltd.NanoPass, a company specializing in intradermal delivery, concluded multiple seasonal flu studies as well as the world's first intradermal H1N1 pandemic flu vaccine study, demonstrating equivalent or superior immunogenicity to standard intramuscular delivery using only 20% of the dose [i,ii,iii]. NanoPass has licensed its technology for various indications to Janssen Pharmaceuticals Inc. (pharmaceuticals companies of Johnson & Johnson (J&J) [NYSE:JNJ]), Circassia and IDRI. The Company is backed by prominent investors including IHCV, Ofer Hi-Tech, DPartners, WFD Ventures and Elcam Medical. About MicronJet600 MicronJet is a microneedle-based device for ID delivery of vaccines and drugs, enabling consistent and simple delivery of therapeutics directly into the skin. MicronJet has proven efficacy and safety in multiple applications including flu vaccines and insulin. MicronJet is approved for marketing in various territories including the USA, for use by health care professionals for intradermal delivery (see label). i Hung IFN et al. Quantitative and qualitative analysis of antibody response after dose sparing intradermal 2009 H1N1 vaccination. Vaccine. 2012;30(17):2707-8. ii Van Damme P et al. Safety and efficacy of a novel microneedle device for dose sparing intradermal influenza vaccination in healthy adults. Vaccine. 2009;27(3):454-9. iii. Hung IFN et al . Dose sparing intradermal trivalent influenza (2010/2011) vaccination overcomes reduced immunogenicity of the 2009 H1N1 strain. Vaccine. 2012;30(45):6427-6435. Contact: Yotam Levin, CEO: +972-523-392727 email@example.com SOURCE NanoPass Technologies LTD.